JWG-071

Cat. No.:	HY-108886
CAS No.:	2250323-50-1
Molecular Formula:	$C_{34}H_{44}N_8O_3$
Molecular Weight:	613
Target:	ERK
Pathway:	MAPK/ERK Pathway; Stem Cell/Wnt
Storage:	Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year



SOLVENT & SOLUBILITY

In Vitro

DMSO : 100 mg/mL (163.13 mM; Need ultrasonic)

Preparing Stock Solutions	Solvent / Mass / Concentration	1 mg	5 mg	10 mg
	1 mM	1.6313 mL	8.1566 mL	16.3132 mL
	5 mM	0.3263 mL	1.6313 mL	3.2626 mL
	10 mM	0.1631 mL	0.8157 mL	1.6313 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline
   Solubility: ≥ 2.5 mg/mL (4.08 mM); Clear solution
2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
   Solubility: ≥ 2.5 mg/mL (4.08 mM); Clear solution
3. Add each solvent one by one: 10% DMSO >> 90% corn oil
   Solubility: ≥ 2.5 mg/mL (4.08 mM); Clear solution

BIOLOGICAL ACTIVITY

Description

JWG-071 is the kinase-selective chemical probe for ERK5. JWG-071 inhibits ERK5 and LRRK2 with IC_{50} values of 88nM and 109 nM, respectively[1].

IC_{50} & Target

ERK5
88 nM (IC_{50})

In Vitro

JWG-071 inhibits ERK5 and LRRK2 with IC_{50} of 88 and 109 nM, respectively[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

CUSTOMER VALIDATION

- Exp Mol Med. 2023 Jun 19.

See more customer validations on www.MedChemExpress.com

REFERENCES

[1]. Wang J, et al. Structural and Atropisomeric Factors Governing the Selectivity of Pyrimido-benzodiazipinonesas Inhibitors of Kinases and Bromodomains. ACS Chem Biol. 2018 Sep 21;13(9):2438-2448

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA